ARTICLE | Company News
AstraZeneca to reassess ZD0473
September 4, 2001 7:00 AM UTC
Anormed (TSE:AOM) said that partner AstraZeneca (AZN; LSE:AZN) will reassess the design and timetable for the Phase III clinical trial program of AOM's ZD0473 platinum-based therapeutic. According to ...